![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Chromogenex | LSE:CGX | London | Ordinary Share | GB00B0B7XX32 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.325 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:8705Y Chromogenex PLC 25 June 2007 Chromogenex plc New Product Launch An advanced system designed to help people stop smoking has been launched by AIM-listed medical and aesthetic laser device company Chromogenex. With the UK's smoking in public places ban coming into effect on 1 July 2007, the Nicolite laser has been introduced to meet the anticipated demand for such aids. Nicolite is a laser system which uses a coherent beam of light of low power to stimulate the release of endorphins by the body. Endorphins are the body's natural painkillers and research suggests that endorphins also help to suppress physical cravings such as the desire for nicotine. Smoking cessation is a multi million pound market and reports suggest that with the UK's new mandatory ban on smoking in public places the demand for smoking cessation treatments will rise rapidly. Peter McGuinness, Chairman of Chromoegenex, commented: 'Our Nicolite system will be rolled out over the forthcoming months into the 1200 plus clinics registered to provide laser treatment in the UK. As well as servicing this rapidly growing market we also plan to sell the product internationally through our existing distribution network.' - ends - For further information: Chromogenex plc 020 8434 0540 Peter McGuinness, Chairman 07775 834 777 Blue Oar 020 7448 4400 Jerry Keen/Romil Patel Threadneedle Communications 020 7936 9605 Graham Herring/Josh Royston 07793 839 024 Notes to Editors: Chromogenex plc is a profitable and established medical and aesthetic laser device company that joined AIM, part of the London Stock Exchange in June 2005. Its principal products include: * The ChromoliteTM, a safe and effective intense pulsed light device for treating unwanted hair, skin pigmentation and thread vein removal. The Chromolite received FDA-approval in January 2006 to distribute its products in the US. * The NLiteTM-V, a patented pulsed-dye laser system initially developed to treat vascular lesions, but proven it to be equally effective in treating Acne Vulgaris (the world's commonest skin disease), psoriasis, which affects 3% of the population and also skin rejuvenation by rebuilding collagen in the skin. * 'Smoothshapes(R) 100' is a painless, non-invasive laser-based system that works gradually and effectively to improve the appearance of cellulite. * Nicolite is a laser system targeting smoking cessation which uses a coherent beam of light of low power to stimulate the release of endorphins by the body. Chromogenex's products are technically advanced and are well protected by sufficient patent protection. The current range is clinically proven and conforms to the most stringent medical standards. Its products are also supported by world-leading luminaries in dermatology, including Dr Tony Chu, a leading UK authority on acne. In October 2003, Dr Chu published positive results of his clinical trials in the Lancet proving the efficacy of NLiteTM-V for the treatment of Acne Vulgaris. The medical and aesthetic marketplace is a multi-billion dollar market, the acne sector alone being estimated at around five billion dollars. Chromogenex is well positioned to exploit this massive and ever increasing area. This information is provided by RNS The company news service from the London Stock Exchange END PRLSEUFEESWSEDM
1 Year Chromogenex Chart |
1 Month Chromogenex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions